TLR3 and neoplasm: Interestingly, activation of multiple TLRs using a combination of TLR3, TLR4, and TLR7 ligands resulted in tumor rejection in 50% of mice in a B16-OVA tumor model with poor immunogenicity [62], increasing innate immunity and CD8+ and CD4+ T-cell responses.